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Lipid dropletsProliferation of cells under hypoxia is facilitated bymetabolic adaptation, mediated by the transcriptional activa-
tor Hypoxia Inducible Factor-1 (HIF-1). HIF-1α, the inducible subunit of HIF-1 is regulated by oxygen as well as
by oxygen-independent mechanisms involving phosphorylation. We have previously shown that CK1δ phos-
phorylates HIF-1α in its N-terminus and reduces its afﬁnity for its heterodimerization partner ARNT. To investi-
gate the importance of this mechanism for cell proliferation under hypoxia, we visually monitored HIF-1α
interactions within the cell nucleus using the in situ proximity ligation assay (PLA) and ﬂuorescence recovery
after photobleaching (FRAP). Both methods show that CK1δ-dependent modiﬁcation of HIF-1α impairs the for-
mation of a chromatin bindingHIF-1 complex. This is conﬁrmed by analyzing expression of lipin-1, a direct target
of HIF-1 that mediates hypoxic neutral lipid accumulation. Inhibition of CK1δ increases lipid droplet formation
and proliferation of both cancer and normal cells speciﬁcally under hypoxia and in an HIF-1α- and lipin-1-
dependent manner. These data reveal a novel role for CK1δ in regulating lipid metabolism and, through it, cell
adaptation to low oxygen conditions.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Oxygen deprivation of cells and tissues (hypoxia) causes a dramatic
alteration in gene expression and characterizes major pathological pro-
cesses like ischemia and cancer. The response to hypoxia is mainly me-
diated by the hypoxia-inducible factors (HIFs) that control the
expression of genes involved inmetabolic reprogramming aswell as an-
giogenesis, cellular proliferation and survival under low oxygen condi-
tions. HIFs are therefore essential for adaptation to hypoxia that
allows cancer cell proliferation in the hypoxic tumormicroenvironment
or survival of normal cells in ischemic tissue [1,2]. A major part of this
adaptation involves HIF-1-mediated stimulation of anaerobic carbohy-
drate metabolism and repression of oxidative phosphorylation [3]. Inyl hydrocarbon receptor nuclear
lsmoothmusclecells;PLA,prox-
tobleaching.
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. This is an open access article underaddition, HIF-1 is implicated in lipid metabolism by supporting fatty
acid synthesis via glutamine metabolism [4], decreasing β-oxidation of
fatty acids [5], and increasing lipin-1-dependent neutral lipid synthesis
and lipid droplet formation [6].
HIFs act as heterodimers and consist of the regulatory HIFα subunits
and the constitutively expressedHIFβ (or aryl hydrocarbon receptor nu-
clear translocator; ARNT) subunit. Under normal oxygen levels, HIF-1α
is modiﬁed by prolyl hydroxylases (PHDs), polyubiquitinated and de-
graded by the proteasome [7]. Under lowoxygen tension, hydroxylation
is inhibited, and HIF-1α is stabilized and translocated into the nucleus
where it interacts with ARNT to form an active DNA-binding heterodi-
mer that associates with hypoxia-response elements (HREs) and acti-
vates the transcription of target genes.
HIF-1α expression and transcriptional activity are additionally regu-
lated by oxygen independent mechanisms involving the NF-κB, PI3-K,
MAPK and STAT3 pathways [8,9] or interactions with many other pro-
teins including HSP90, RACK1 and MgcRacGAP [10–13]. A key aspect
of HIF-1α regulation involves its post-translationalmodiﬁcation by pro-
tein kinases. Phosphorylation can regulate HIF-1α protein stability, as
reported for modiﬁcations introduced by kinases GSK3, PLK3 and
CDK1 [14–16], or it can affect HIF-1 transcriptional activity. In the latterthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mediated nuclear export of HIF-1α, thereby increasing its nuclear accu-
mulation and activity [17,18]. In addition, we have recently shown that
casein kinase 1δ (CK1δ) targets Ser247 at the PAS B domain of HIF-1α,
causing reduction of its in vitro afﬁnity for ARNT and inhibition of its
transcriptional activity [19].
CK1δ is a member of the CK1 protein kinase family that is composed
of seven distinct mammalian isoforms (α, β, γ1, γ2, γ3, δ and ε) and
their splice variants. Although most of these isoforms are ubiquitously
expressed and involved in diverse cellular functions such as cell cycle
progression, DNA damage response and circadian rhythms, their
regulation is complex and poorly understood [20].
In this work, we investigate the effects of CK1δ-mediated phosphor-
ylation on HIF-1 function in intact and living cells and analyze its
involvement in the metabolic reprogramming and proliferation of
cells under hypoxia. Our data demonstrate a novel role of CK1δ in
limiting lipid biosynthesis and cell proliferation under hypoxia by
inhibiting full activation of the HIF-1/lipin-1 axis.
2. Materials and methods
2.1. Plasmids and antibodies
Cloning of HIF-1α1-347 (N-terminal fragment) into pBS-SK(+) and
HIF-1α348-826 (ΔΝ) into pGEX-4T-1 was described previously [21].
The corresponding cDNA inserts were inserted as BamHI fragment
into the pEGFP-C1 vector. pEGFP-HIF-1αS247A and pEGFP-HIF-
1αS247D plasmids were previously described [19]. pCDNA3.1-CK1δ
and pCDNA3.1-CK1δ-K38M [22,23] were kindly provided by Uwe
Knippschild (Centre of Surgery, University of Ulm, Germany). Antibod-
ies used included: afﬁnity puriﬁed rabbit polyclonal antibodies against
HIF-1α [24], lipin-1 and lipin-2 [25], mouse monoclonal antibody
against ARNT (BD Biosciences), goat polyclonal antibody against
GFP (SICGEN) and rabbit polyclonal antibodies against actin, tubulin
(Cell Signaling) or CK1δ (Santa Cruz Biotechnology).
2.2. Cell culture, transfection, reporter gene assays and chromatin
immunoprecipitation
Cells were cultured in DMEM, for HeLa and Huh7 cells, or DMEM F-
12, for human bronchial smooth muscle (hBSM) cells (Lonza), contain-
ing 10% FCS and 100 U/ml penicillin/streptomycin (Biochrom). Cells
were grown in a 37 °C incubator with 5% CO2. For hypoxic treatment,
cells were exposed for 4–24 h to 1% O2, 94% N2 and 5% CO2 in an IN
VIVO2 hypoxia workstation (Baker Ruskinn). When required, cells
were treated for 4–24 h with CK1δ inhibitor D4476 (10 μΜ, Cayman
Chemical) or kaempferol (50–100 μΜ, Sigma) using a 10 mM stock
solution in dimethyl sulfoxide (Applichem). Transient transfections,
reporter gene assays and chromatin immunoprecipitation were
performed as previously described [6].
2.3. siRNA-mediated silencing
HeLa cells were incubated in serum-free DMEM for 4 h with siRNA
(10 nM) against HIF-1α (Qiagen) or Lpin1 [6] in the presence of
Lipofectamine™ RNAiMAX (Invitrogen). AllStars siRNA (Qiagen) was
used as negative control.Fig. 1.HIF-1α/ARNT complexes can be speciﬁcally detected and quantiﬁedby in situ PLA inHeLa
detection of HIF-1α/ARNT interaction using simultaneous incubationwith both primary anti-HIF
with a single primary antibody (panels iii–vi) or noprimary antibodies (panels vii and viii)was u
dots while the corresponding panels i′–viii′ show the cell nuclei stained with DAPI. (b) Detectio
for 4 h in the absence or presence of kaempferol (50–100 μΜ). (c) Twenty hours post-transfect
O2) and HIF-1α/ARNT complexes were detected by in situ PLA. Arrows point to transfected ce
average number of nuclear dots per cell ± SEM (n= 50). Inset in (c): immunobloting analysis
1-347.2.4. Western blot and ﬂuorescence microscopy
Immunoblotting and immunoﬂuorescence microscopy were carried
out as previously described [6]. Western blot images were taken using
an Uvitec Cambridge Chemiluminescence Imaging System with the
help of Alliance Software (ver. 16.06) and quantiﬁed by Uviband
Software (ver. 15.03) provided with the instrument (Uvitec Cam-
bridge). To visualize lipid droplets, cells were stained with Nile Red
(Sigma; 0.1 μg/ml in PBS) for 15 min, washed with PBS and mounted
on slides. Quantiﬁcation of the surface covered by Nile Red ﬂuorescence
was performed with the public domain software for image analysis
‘ImageJ’ and expressed as pixels/cell [26].
2.5. Cell proliferation assay
HeLa or hBSM cells (1.000–2.000 cells/well) were seeded into 96-
well plates and incubated for 24 h before being treated with 10 μΜ
D4476 or with DMSO as solvent control for the indicated periods
under normoxic or hypoxic conditions. At the end of the incubation
period, cell proliferation was determined using the “CellTiter 96
Aqueous One Solution Cell Proliferation Assay” kit (Promega). Values
were normalized by control experiments in the absence of cells in 96-
well plates supplied with culture medium and DMSO or D4476 alone.
2.6. In situ proximity ligation assay
The in situ proximity ligation assay (PLA) allows the visualization
and subcellular localization of protein–protein interactions in individual
ﬁxed cultured cells, using secondary antibodies with attached oligonu-
cleotides. When a pair of antibodies binds in proximity, the attached ol-
igonucleotides can guide the creation of a DNA circle by ligation. This
circle then templates a local rolling circle ampliﬁcation reaction,
whose product is easily detectable by FISH [27]. The HIF-1α interaction
with ARNT under hypoxia wasmonitored in HeLa cells grown on slides.
After appropriate incubation, cells were ﬁxed with 3% formaldehyde in
PBS for 5 min, permeabilized with PBS/Triton 1% for 15 min at 4 °C,
incubated with anti-HIF-1α and/or anti-ARNT antibodies for 16 h
at 4 °C and processed using the Duolink II Fluorescence Kit
(Olink Bioscience). Slides were counterstained with DAPI (100 μg/ml)
before mounting. Images of in situ PLA experiments were taken in a
Zeiss Axioplan ﬂuorescence microscope using an AxioCam MRm CCD
sensor and 40× objective with ﬁlters for DAPI, FITC and Cy3. PLA signals
were digitally quantiﬁed using the ITCN tool of public domain software
for image analysis ImageJ [28].
2.7. Fluorescence recovery after photobleaching (FRAP) experiments and
data analysis
HeLa cells were plated on 35-mm high glass-bottom Ibidi μ-dishes,
in phenol red-free medium (Invitrogen). FRAP experiments were
conducted on a Leica TCS SP5 microscope equipped with a 63 × 1.4
numerical aperture oil-immersion lens. During experiments, cells
were maintained at 37 °C and 5% CO2. A deﬁned circular region of
2 μm diameter (Region of Interest 1 — ROI1) was placed to the nuclear
midpoint of cells. GFP was excited using the 488 nm Argon laser line.
Fifty pre-bleach images were acquired with 2% of the 488 nm line
at 60% Argon laser intensity, followed by double bleach pulses on ROI1
of 0.066 s using the 476 nm and 488 nm laser lines, combined atcells. (a) Cellswere incubated at normoxia or hypoxia (1%O2) for 4 h and processed for the
-1 and anti-ARNT antibodies and the in situ PLAmethod (panels i and ii). Treatment of cells
sed as negative controls. Panels i–viii showmicroscopic images of the PLA signal as nuclear
n of HIF-1α/ARNT complexes by in situ PLA in HeLa cells incubated under hypoxia (1% Ο2)
ion, HeLa cells expressing GFP or GFP-HIF-1α 1-347 were incubated for 4 h in hypoxia (1%
lls. Left panels: microscopical images. Right panels: quantiﬁcation of results presenting the
of cell lysates with an anti-GFP antibody to show expression of GFP alone or GFP-HIF-1α
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ROI1 was successfully bleached. Following bleaching, 300 images were
recorded at 0.066 s intervals. Mean ﬂuorescence intensities of the
ROI1, the whole nucleus (ROI2) and an area outside the nucleus for
background correction (ROI3) were quantiﬁed and exported as
comma-separated values. Quantitative analysis of the experimental
recovery curves was performed using easyFRAP [29] and model-based
analysis was performed using the parameter inference method
described previously [30].2.8. Statistical analysis
Statistical differences between two groups of data were assessed
using the unpaired t-test or the 1-way ANOVA test (for FRAP analysis
results) in the GraphPad Prism version 5.04 software; P b 0.05 was
considered to be signiﬁcant (*P b 0.05; **P b 0.01; ***P b 0.001).3. Results
3.1. Detection and relative quantiﬁcation of HIF-1α/ARNT complex
formation using in situ PLA in HeLa cells
In order to study the regulation of complex formation of endogenous
HIF-1 in intact cells, we applied the in situ proximity ligation assay
(PLA). Using this method, the HIF-1α/ARNT interaction was monitored
in HeLa cells that were incubated under normoxic or hypoxic
conditions. Following treatment with both anti-HIF-1α and anti-ARNT
primary antibodies and analysis by in situ PLA, a very weak signal
could be detected in cells incubated under normoxia while, in contrast,
the signal was drastically ampliﬁed in cells grown under hypoxic condi-
tions (Fig. 1a, panels i and ii and chart). The detected signals were
speciﬁc for the HIF-1α/ARNT complex as no signal was obtained when
one or both of the primary antibodies were omitted (Fig. 1a, panels
iii–viii). We, therefore, concluded that in situ PLA could be used for
speciﬁc detection of HIF-1α/ARNT heterodimerization in intact cells.
To validate in situ PLA as a means to determine the extent of HIF-
1α/ARNT complex formation we used two different approaches.
Kaempferol, a dietary ﬂavonoid causes mislocalization of HIF-1α to
the cytoplasm by inactivation of ERK1/2 [31]. Thus, treatment with
kaempferol (50–100 μΜ) under hypoxic conditions is expected to lead
to decreased numbers of active HIF-1 complexes inside the nucleus.
Indeed, as shown in Fig. 1b, treatment of HeLa cells with kaempferol
resulted in a signiﬁcant and concentration-dependent decrease of
nuclear PLA signals. In the second approach, we attempted to disrupt
formation of HIF-1α/ARNT complexes when HIF-1α and ARNT proteins
are both simultaneously present inside the nucleus. To this end, we
used the N-terminal part of HIF-1α, containing its heterodimerization
domain that is known to competewith endogenousHIF-1α for its inter-
actionwith ARNT [32]. Overexpression of this domain (HIF-1α1-347) as
a GFP-tagged protein in HeLa cells led to a strong decrease in the
number of PLA signals compared with cells expressing GFP alone
(Fig. 1c; white arrows). Taken together, our results show that in situ
PLA can be reliably used not only to detect but also to quantify the
relative extent of HIF-1α/ARNT interaction inside the nucleus.Fig. 2. Overexpression of CK1δ impairs and inhibition of CK1δ by D4476 increases formation of
CK1δ and pEGFP plasmids. Twenty hours post-transfection cells were incubated under hypoxia
HIF-1α/ARNT complexes, in the absence or presence of D4476 (10 μΜ) under hypoxia (1% O
quantiﬁcation of results presenting the average number of nuclear dots per cell ± SEM (n =
under normoxia or hypoxia (1% O2) in the absence or presence of D4476 (10 μΜ). Results are s
themean of three independent experiments performed in triplicate ±SEM. (d)Western blot an
presence of D4476 (10 μΜ), for detection of HIF-1α and ARNT protein levels. (e) Histogram
quantiﬁcation of blots from three independent experiments performed as in (d).3.2. Overexpression of CK1δ impairs and inhibition of CK1δ stimulates HIF-
1α/ARNT complex formation under hypoxic conditions
Having established the suitability of in situ PLA for generating
quantiﬁable data in a cell-based system, we investigated the effect
of CK1δ on the formation of HIF-1 complexes. HeLa cells were co-
transfected with a CK1δ overexpressing plasmid (pcDNA3.1-CK1δ) or
the corresponding empty vector (pcDNA3.1) and a GFP expressing
plasmid (pEGFP; to detect transfected cells) and incubated under
hypoxic conditions (Supplementary Fig. 1a). Visualization and quantiﬁ-
cation of the PLA signals show a signiﬁcant decrease in the number
of HIF-1α/ARNT complexes speciﬁcally in cells that overexpress CK1δ
compared to control cells that are transfected with the empty vector
(Fig. 2a) Therefore, CK1δ does indeed inhibit HIF-1 heterodimerization
in intact cells in accordancewith our previous in vitro experiments [19].
To conﬁrm the negative effect of CK1δ on HIF-1 complex assembly,
we used a potent and speciﬁc (at 10 μΜ) CK1δ inhibitor, D4476, which
has recently become commercially available and used successfully for
targeting CK1δ [33–35]. Treatment with the D4476 (10 μΜ), resulted in
a signiﬁcant increase in the number of nuclear HIF-1α/ARNT complexes,
as shown by in situ PLA in HeLa cells incubated under hypoxia (Fig. 2b).
In the presence of D4476, transcriptional activity of endogenous HIF-1
was also drastically enhanced in HeLa cells grown under hypoxia
(Fig. 2c). Interestingly, analysis by western blotting conﬁrmed that the
stimulation of HIF-1 transcriptional activity by D4476 was not due to
an effect on HIF-1α or ARNT expression levels, which remained con-
stant both in the presence and absence of the inhibitor (Fig. 2d and e).
Taken together, our data verify that CK1δ inhibits HIF-1 activity by
impairing the formation of HIF-1α/ARNT heterodimers.3.3. Phospho-sitemutation S247A and inhibition of CK1δ by D4476 both re-
duce nuclear mobility of HIF-1α in living cells
To investigate the effect of CK1-mediated phosphorylation on HIF-1
in living cells, we applied ﬂuorescence recovery after photobleaching
(FRAP) for the determination of HIF-1α intranuclear mobility and
kinetics that reﬂect its ability to form heterodimers that bind stably to
chromatin. To this end, we used HeLa cells ectopically expressing GFP-
HIF-1α or its mutant forms that abolish or mimic its CK1δ-dependent
phosphorylation (Supplementary Fig. 1b). Mutation of Ser247 to
alanine (S247A) has been shown to increase the afﬁnity of HIF-1α for
ARNT in in vitro binding assays,whereas, the phosphomimeticmutation
of the same site to aspartate (S247D) has been shown to exhibit the
opposite effect [19]. As negative control, we used HeLa cells expressing
a GFP-tagged fragment of HIF-1α that lacks the heterodimerization
domain (HIF-1α-ΔΝ) and has, therefore, no ability to form heterodi-
mers. FRAP was performed 24 h post-transfection by bleaching a
circular area within the nucleus and then monitoring the recovery of
ﬂuorescence in the bleached region over time (Fig. 3a, circles). A visual,
qualitative examination of the resulting FRAP recovery curves (Fig. 3b
and Supplementary Fig. 2) revealed distinct dynamics for the GFP-HIF-
1α constructs under normoxia. GFP-HIF-1α-ΔΝ is characterized by
rapid and full recovery of ﬂuorescence, indicating a purely diffusive
behavior. Wild-type HIF-1α and its phosphomimetic mutant (S247D)
are characterized by similar dynamics, whereas S247A, which is unableHIF-1α/ARNT complexes. (a) HeLa cells were co-transfected with pcDNA3.1 or pcDNA3.1-
(1% O2) for 4 h and HIF-1α/ARNT complexeswere detected by in situ PLA. (b) Detection of
2) for 4 h, by in situ PLA. For (a) and (b): left panels: microscopical images. Right panels:
50). (c) Determination of HIF-1 transcriptional activity in HeLa cells incubated for 16 h
hown as fold increase in relation to the corresponding normoxic conditions and represent
alysis of HeLa cells incubated for 4 h under normoxia or hypoxia (1% O2) in the absence or
s show the HIF-1α/actin (left) or ARNT/actin (right) protein levels ratio according to
Fig. 3. Phospho-site mutation S247A and inhibition of CK1δ by D4476 reduce nuclear mobility of HIF-1α in living cells. (a) Transfected HeLa cells overexpressing the indicating HIF-1α
forms tagged with GFP were processed for FRAP analysis 24 h post-transfection. Representative time-lapse images of cells are shown for each GFP-tagged protein. Circles indicate the
bleached region. (b) Analysis of FRAP recoveries. Curves represent the mean corrected ﬂuorescence intensities over time for GFP-tagged HIF-1α-ΔΝ, wt HIF-1α, HIF-1α S247A, HIF-1α
S247D and wt HIF-1α in the presence of D4476, as indicated.
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recovery was further decreased when cells expressing wild type GFP-
HIF-1αwere treated with the CK1δ inhibitor D4476.
Quantitative analysis of the experimental recovery curves was
performed using easyFRAP [29], which allowed the extraction of values
for mobile fraction and half-maximal recovery time (t1/2) and model-
based analysis [30], which permitted determination of the underlying
kinetic parameters, namely diffusion coefﬁcient (associated with theTable 1
Measured and kinetic parameter estimates of FRAP experiments.
easyFRAP
GFP-HIF-1α construct N t1/2 (s) Mobile fraction
ΔN 18 0.15 ± 0.07 0.95 ± 0.04
wt 14 0.29 ± 0.10 0.87 ± 0.11
S247D 9 0.35 ± 0.19 0.93 ± 0.03
S247A 13 0.74 ± 0.68 0.82 ± 0.16
wt + D4476 15 1.87 ± 2.04 0.70 ± 0.21
EasyFRAP: values of half-maximal recovery time (t1/2) and mobile fraction for different GFP-HI
Model-based analysis: kinetic parameter estimates of FRAP recovery curves for different GFP-HIF
recovery curves corresponding to different cells (N represents the number of cells analyzed inspeed of diffusion of free molecules), bound fraction (deﬁned as the
fraction of molecules that are bound at any given time) and residence
time (deﬁned as the time a molecule spends on average in the bound
state). These values (Table 1) conﬁrmed the visual observations. More
speciﬁcally, GFP-HIF-1α-ΔΝ was highly mobile and exhibited a small
t1/2, signiﬁcantly faster diffusion coefﬁcient and negligible bound
fraction and residence time. These results are consistentwith the inabil-
ity of GFP-HIF-1α-ΔΝ to interact with ARNT and bind to chromatin.Model-based analysis
Diffusion coefﬁcient (μm2/s) Bound fraction Residence time (s)
47.1 ± 5.1 0.01 ± 0.01 –
21.6 ± 16 0.09 ± 0.04 19.2 ± 6.3
12.5 ± 6.9 0.12 ± 0.05 15.4 ± 5.4
13.6 ± 11.8 0.18 ± 0.13 20.1 ± 6.6
10.8 ± 11.6 0.28 ± 0.14 20.8 ± 6.6
F-1α constructs, processed as described in Materials and methods.
-1α constructs. Numerical values correspond to themean± standarddeviation of different
each condition).
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between all forms of full-length GFP-HIF-1α. Wild-type GFP-HIF-1α
and its phosphomimetic mutant S247D were characterized by similar
values for t1/2, mobile fraction and bound fraction (no statistically
signiﬁcant differences were observed, P N 0.05 in all cases), indicating
quantitative phosphorylation of GFP-HIF-1α by CK1δ in living cells. In
contrast, the phosphodeﬁcient S247A mutant exhibited signiﬁcantly
higher residence time than the mutant S247D (P b 0.01), indicative of
higher afﬁnity for its heterodimerization partner and stronger binding
to chromatin components. In cells treated with D4476 and for wild-
type GFP-HIF-1α, recovery was slower (P b 0.05 compared to wild-
type in absence of D4476; P b 0.01 compared to S247D),mobile fraction
was lower (P b 0.05 compared to either wild-type minus D4476 or
S247D), bound fraction was higher (P b 0.01 compared to wild-type
minus D4476) and residence time was longer (P b 0.01 compared to
S247D). The differences between mutant GFP-HIF-1α-S247A and
wild-type GFP-HIF-1α plus D4476, although they did not reach statisti-
cal signiﬁcance, indicate that modiﬁcation of HIF-1α Ser247may not be
the sole involvement of CK1δ in HIF-1 regulation.
3.4. Inhibition of CK1δ-dependent phosphorylation of HIF-1α facilitates
metabolic adaptation of cells to hypoxia
To evaluatewhether the enhanced HIF-1 heterodimerization caused
by CK1δ inhibition is productive in terms of stimulated transcription of
HIF-1 target genes, we investigated binding of HIF-1 to the HRE in the
promoter of Lpin1, a recently identiﬁed hypoxia and HIF-1 regulated
gene, the product of which, lipin-1, has phosphatidic acid phosphatase
activity and is required for up-regulation of triglyceride synthesis and
lipid droplet formation under hypoxia [6]. This was ﬁrst done by chro-
matin immunoprecipitation using Huh7 cells, in which induction of
the Lpin1 gene by hypoxia is more pronounced [6]. As anticipated, the
Lpin1 promoter region was enriched in anti-HIF-1α immunoprecipi-
tates from hypoxically treated cells in comparison to rabbit IgG immu-
noprecipitates or anti-HIF-1α immunoprecipitates from normoxic
cells. Furthermore, isolation of the promoter was signiﬁcantly enhanced
whenD4476was present (Fig. 4a). Up-regulation of lipin-1 synthesis by
CK1 inhibition was further conﬁrmed by analysis of lipin-1 expression
levels in HeLa cells grown under the same conditions. As shown in
Fig. 4b and c, lipin-1 expression was signiﬁcantly increased by D4476
treatment under hypoxia, while HIF-1α protein levels remained
unaffected. At the same time, expression of lipin-2, which is not an
HIF-1 target, remained unchanged (Fig. 4b). We, therefore, conclude
that HIF-1α association with the Lpin1 promoter is stimulated when
CK1δ is inhibited, thereby enhancing lipin-1 synthesis.
To investigate the effect of these changes on triglyceridemetabolism
we examined the formation of lipid droplets in HeLa cells incubated
with D4476 for 24 h under normoxic or hypoxic conditions. Treatment
with D4476 signiﬁcantly increased lipid droplet formation under
hypoxia (Fig. 5a, left panel and Supplementary Fig. 3a), indicating
increased triglyceride production via up-regulation of the HIF-1 and
lipin-1. To see if the changes triggered by CK1δ inhibition would affect
cellular adaptation to hypoxia, we measured the proliferation of HeLa
under the same conditions. Inhibition of CK1δ did not signiﬁcantly affect
cellular growth rate under normoxic conditions. However, under hyp-
oxia, D4476 caused a small but statistically signiﬁcant increase in cell
proliferation, in agreement with its positive effect on HIF-1 activity
(Fig. 5a, right panel). We then tested the effects of CK1δ inhibition on
lipid droplet accumulation and cell proliferation in normal, non-cancer
cells by using primary, non-transformed human bronchial smooth
muscle (hBSM) cells. The results were similar as with HeLa cells
(Fig. 5b and Supplementary Fig. 3b), suggesting that the CK1δ-HIF-1α-
lipin-1 regulatory axis operates irrespective of the cellular transforma-
tion status.
To conﬁrm the loss-of-function experiments using CK1δ inhibition
in a positive way, we then examined lipid droplet formation in HeLacells overexpressing catalytically active CK1δ or, as negative control,
the catalytically inactive CK1δ K38M mutant (Supplementary Fig. 1a)
[23]. Under hypoxia, lipid droplet formation was decreased when the
wild type form of CK1δ was overexpressed, whereas expression of its
mutant inactive form K38M did not have any effect on lipid droplet
formation (Fig. 6). We conclude that CK1δ limits neutral lipid synthesis
under hypoxia, and this is most likely mediated by inhibition of
heterodimerization and transcriptional activity of HIF-1.
3.5. Stimulation of cell proliferation under hypoxia by CK1δ inhibition is
HIF-1- and lipin-1-dependent
The ﬁnding that inhibition of CK1δ stimulates cell proliferation
under hypoxia is novel and unanticipated. Our data so far suggest that
this is the result of increased HIF-1 and lipin-1 activity, triggered by
CK1δ inhibition, but we cannot exclude the possibility that cellular
proliferation is affected by an unrelated CK1δ target. To address this
issue, the involvement of HIF-1 and lipin-1 in adaptation of cells to a
hypoxic environment was tested by siRNA-mediated repression of
HIF-1α or lipin-1 expression in HeLa cells, kept under normoxia or hyp-
oxia and treated with D4476.
In agreement with our previously published data [6], the siRNA
against HIF-1α was effective in reducing the expression of both HIF-
1α and lipin-1 under hypoxia (Fig. 7a, upper panel), while the siRNA
against lipin-1 decreased the expression of lipin-1 under all conditions
(Fig. 7b, upper panel). As expected, knocking down HIF-1α did not
affect cell proliferation under normoxia, irrespective of D4476 treat-
ment. However, hypoxic stimulation of proliferation and its further
enhancement by D4477 were both greatly abolished when HIF-1α
expression was silenced (Fig. 7a, bottom panel). Depletion of lipin-1
did not signiﬁcantly alter cellular proliferation under normoxia. In
contrast, suppression of lipin-1 expression signiﬁcantly decreased
hypoxia-stimulated cellular proliferation, and it almost completely
neutralized the positive effect of CK1δ inhibition (Fig. 7b, lower
panel). These data lead to the conclusion that increased proliferation
of cells under hypoxia requires HIF-1 and also, surprisingly, a lipin-1-
mediated function such as, possibly, up-regulation of lipid droplet
formation. CK1δ restricts this phenomenon and can limit cellular
proliferation under hypoxia by modifying HIF-1α and impairing its as-
sociation with ARNT and DNA (Fig. 7c).
4. Discussion
As HIF-1 is associated with severe pathological conditions such as
tissue ischemia and cancer, it is vital to identify in detail the mecha-
nisms that affect its activity in order to develop novel therapeutic
approaches. In this study, we documented the negative effect of CK1δ
on HIF-1α/ARNT complex formation as well as HIF-1 DNA binding and
transcriptional activity, and how this affects metabolic adaptation and
proliferation of cells that grow under hypoxia. More speciﬁcally, we
have shown that CK1δ, by inhibiting HIF-1, impairs lipin-1 expression
and lipid droplet formation, processes that are essential for maintaining
a high proliferation rate under hypoxia. Therefore, CK1δ appears to have
an anti-proliferative role under hypoxia, which may promote cellular
homeostasis as well as protect from cancer progression.
It has long been established that HIF-1 is heavily implicated in the
shift of energy metabolism in hypoxic cancer cells from mitochondrial
oxidative phosphorylation to glycolysis [36]. However, the effects of
hypoxia and HIF-1 on lipidmetabolism have only recently been studied.
Increased lipid droplet accumulation observed under hypoxia can be
explained by enhanced de novo fatty acid synthesis, using the acetyl-
CoA, overproduced by the combination of glycolytic shift andmitochon-
drial dysfunction [37,38], and fatty acid synthase (FASN), an essential
lipogenic enzyme overexpressed under hypoxia and strongly correlated
with cancer progression [39]. Furthermore, recent studies signify the
uptake of fatty acids from the growth medium as an important source
1136 M. Kourti et al. / Cellular Signalling 27 (2015) 1129–1140
Fig. 5. CK1δ inhibition increases lipid accumulation and cell proliferation under hypoxic conditions. Treatment with D4476 (10 μΜ) of HeLa (a) or hSMB (b) cells kept under normoxia or
hypoxia (1% O2). Left: ﬂuorescence microscope images of cells incubated under normoxia or hypoxia (1% O2) for 24 h in the absence or presence of D4476 (10 μΜ) and stained with Nile
Red to visualize lipid droplets. Right: digitized graph of cell proliferation under normoxia or hypoxia (1% O2) in the absence or presence of D4476 (10 μΜ) after 24 h (a) or 48 h
(b) treatment. Data represent the mean of three independent experiments performed in triplicate and expressed, as percent of the initial number of cells at time zero ± SEM.
1137M. Kourti et al. / Cellular Signalling 27 (2015) 1129–1140of lipids in cancer cells under hypoxia [40]. Fatty acid accumulation can
be further enhanced by suppression of fatty acidβ-oxidation that occurs
under hypoxia [5,41]. Thus, hypoxic cancer cells have to deal with the
excessive accumulation of fatty acids that can cause lipotoxicity and
cell death [42]. According to our model (Fig. 7c), lipotoxicity is avoidedFig. 4. CK1δ inhibition stimulates lipin-1 expression under hypoxic conditions. (a) D4476 increa
ucts ampliﬁed from anti-HIF-1α or rabbit IgG chromatin immunoprecipitates of Huh7 cells, in
(10 μΜ). Bottom: quantiﬁcation of real-time PCR results. Data represent the mean (±SEM) o
HeLa cells incubated for 24 h under normoxia or hypoxia (1%O2) in the absence or presence of D
control. (c) Histogram shows the lipin-1/tubulin protein levels ratio according to quantiﬁcationby storing fatty acids as neutral triglycerides in lipid droplets via HIF-1-
mediated up-regulation of lipin-1 synthesis.
However, the requirement of lipin-1 for the increased proliferation
of cancer cells under hypoxia may not only be attributed to the forma-
tion of lipid droplets, since diacylglycerol (DAG), the direct product ofses the interaction of HIF-1αwith lipin1 promoter.Upper: gel electrophoresis of PCR prod-
cubated for 8 h under normoxia or hypoxia (1% O2) in the absence or presence of D4476
f two independent experiments performed in triplicate. (b) Western blotting analysis of
4476 (10 μΜ), for detection of HIF-1α and lipin protein levels. Tubulinwas used as loading
of blots from three independent experiments performed as in (b).
Fig. 6. Overexpression of active CK1δ impairs lipid accumulation under hypoxic conditions. Left: HeLa cells were co-transfected with pcDNA3.1 or pcDNA3.1-CK1δwt or pcDNA3.1-CK1δ
K38M and pEGFP plasmids. Twenty four hours post-transfection cells were incubated for 24 h under hypoxia (1% O2), stained with Nile Red to visualize lipid droplets and observed by
ﬂuorescence microscope. Right: quantiﬁcation was performed using ImageJ software and represent the mean area ±SEM of Nile Red staining of 50 cells.
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can also be used for the synthesis of the most abundant phospholipids,
phosphatidylethanolamine (PE) and phosphatidylcholine (PC), which
participate in membrane biogenesis [43]. Moreover, phosphatidic acid
(PA) and DAG, substrate and product, respectively, of lipin-1, play im-
portant roles in essential signaling pathways, such as those of mTOR
and PKC, and their relative intracellular levels, which are largely deter-
mined by lipin activity, may also affect cancer cell proliferation [44,
45]. Finally, lipin-1 interacts with and/or modulates the activity of sev-
eral transcription factors, including members of the peroxisome
proliferator-activated receptor (PPAR) family and SREBP, that control
the expression of genes involved in lipid metabolism [46,47]. Whatever
the case may be, inhibition of HIF-1-dependent lipin-1 expression by
CK1δ, appears to restrict cancer cell growth under hypoxia.
Although CK1 isoforms have been implicated in numerous biological
functions and also linked to pathological conditions [20], their involve-
ment in cancer cell proliferation and tumor formation is controversial.
The role of CK1 in the regulation of pathways associatedwith cell prolif-
eration, such as those involving p53 or Wnt, can have positive or nega-
tive effects depending on cell type and conditions [48–50]. Our previous
[19] and current work identiﬁes metabolic adaptation to hypoxia as a
new target of CK1, which, in this case, plays an anti-proliferative role
by impairing the formation of an active HIF-1 heterodimer. This is in
agreement with previous studies examining the effect of CK1 isoforms
on the activity of the p53 tumor suppressor protein. Upon cell stress,
CK1δ/ε phosphorylates p53 in its N-terminal region, weakens the inter-
action with MDM2 and, therefore, stabilizes and activates p53 function
[51]. Along the same line, reduced expression of CK1α/δ/ε isoforms has
been linked to more aggressive carcinoma types, and CK1α has been
shown to act as a tumor suppressor when p53 is inactivated [48]. On
the other hand, there is also evidence for oncogenic functions of CK1
isoforms in certain types of cancer [20]. A problem with these studies
is that expression levels of a CK1 isoform do not necessarily correspond
to phosphorylation levels of CK1 targets, as CK1 isoforms are themselves
subject to post-translational regulation. The complex multi-layer con-
trol of CK1 and its ubiquitous nature create anobstacle in understanding
the possible connection between CK1 regulation and the physiological
response to hypoxia, which require additional extensive studies.
Apart from cancer, where HIF-1 is associated with pathogenesis and
poor patient outcome, HIF-1 has also an important and protective rolein a wide range of disorders characterized by ischemia and inﬂammation
[52]. Studies in animalmodels and patient samples have shown that in is-
chemic tissues that overexpress HIF-1α, the transcription of genes associ-
atedwith angiogenesis, vascular remodeling andmetabolism is activated,
thus, having a favorable impact on tissue health and disease outcome [2].
Moreover, HIF-1α stabilization in conditions such as inﬂammatory bowel
disease, pathogen infection, acute lung injury and organ transplantation
has been associated with beneﬁcial results. So, in these disorders, the
therapeutic efforts are directed towards augmenting HIF-1 activity. Until
now, HIF-1 activators tested for treatment comprise PHD inhibitors that
promote HIF-1α stabilization [52]. Although the stability of its alpha sub-
unit is an essential step, full HIF-1 activation also relies on down-stream
oxygen-independent processes such as dimerization with ARNT. Our
results, showing that inhibition of CK1δ enhances the proliferation of
primary normal hBSM cells under hypoxic conditions, suggest that
stimulation of HIF-1α/ΑRΝΤ complex formation by CK1δ chemical
inhibitors may form the basis of novel therapeutic approaches.
5. Conclusions
CK1δ plays an important role in the cellular response to hypoxia by
controlling HIF-1 complex formation in living cells. Moreover, CK1δ re-
stricts cellular proliferation under hypoxia by limiting HIF-1 activity, re-
ducing induction of lipin-1 and lowering lipid droplet formation. This
novelmetabolic function of CK1δ and itsmodulation by chemical agents
can facilitate the development of molecular strategies for the diagnosis
or treatment of hypoxia-related pathological conditions.
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Fig. 7. Stimulation of cancer cell proliferation by CΚ1δ inhibition is HIF-1α- and lipin-1-dependent. (a and b) Upper panels: results of western blotting analysis for HIF-1α and lipin-1 pro-
tein levels after HIF-1α or lipin-1 silencing, respectively. HeLa cells were transfected with control siRNA or siRNA against HIF-1α or lipin-1, and 24 h post-transfection, incubated for 24 h
under normoxia or hypoxia (1% O2) in the absence or presence of D4476 (10 μΜ). Bottom panels: digitized graph of HeLa cell proliferation, treated in the same conditions as described
above. Data represent the mean of three independent experiments performed in triplicate and expressed, as percent of the initial number of cells at time zero ± SEM. (c) Schematic
model of the mechanism by which CK1δ impairs cell proliferation under hypoxia.
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